eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
 
1/2021
vol. 37
 
Share:
Share:
more
 
 
Review paper

Can the use of benzodiazepines increase the risk of dementia?

Jan Jaracz
1
,
Natalia A. Rakowska
1

1.
Department of Adult Psychiatry, Poznan University of Medical Sciences
Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (1), 53–62
Online publish date: 2021/11/17
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 
1. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger- Gateau P et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008; 64(5): 492–498.
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New England Journal of Medicine. 2012; 367(9): 795–804.
3. Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345: e6231.
4. Bourin M. The problems with the use of benzodiazepines in elderly patients. Encephale. 2010; 36(4): 340–347.
5. Catindig JA, Venketasubramanian N, Ikram MK, Chen C: Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors. J Neurol Sci 2012; 321: 11–16.
6. Chen PL, Lee WJ, Sun WZ, Oyang YJ, Fuh JL. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One. 2012; 7(11): e49113.
7. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH: Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 2010; 67: 114–121.
8. Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther 2017; 9(1): 71.
9. Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2011; 28(1): 7–20.
10. Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12(1):14-17.
11. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O’Meara ES, Longstreth Jr WT et al.: Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66: 336–342.
12. Fourrier A, Letenneur L, Dartigues J, Moore N, Bégaud B. Benzodiazepine use in an elderly community-dwelling population. Eur J Clin Pharmacol 2001; 57(5): 419–425.
13. Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 2012; 66(10): 869–873.
14. Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study BMJ 2016; 352: 90.
15. Holm E, Fosbol E, Pedersen H, Jensen TB, Nielsen M, Weeke P et al. Benzodiazepine use in Denmark 1997–2008. Eur Geriatr Med 2012; 3(5): 299–303.
16. Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case-Control Analysis. Drug Saf 2015; 38(10): 909–919.
17. Islam Md M, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen P-A et al. Benzodiazepine Use and Risk of Dementia in the Elderly Population: A Systematic Review and Meta-Analysis. Neuroepidemiology 2016; 47: 181–191.
18. Kuerbis A, Sacco P, Blazer DG, Moore AA. Substance abuse among older adults. Clin Geriatr Med 2014; 30(3): 629–654.
19. Lagnaoui R., Bégaud B., Moore N., Chaslerie A., Fourrier A., Letenneur L. et al. Benzodiazepine use and risk of dementia: a nested case-control study. Journal of clinical epidemiology 2002; 55(3): 314–318.
20. Lagnaoui R, Tournier M, Moride Y et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing 2009; 38(2): 226–228.
21. Lee J, Jung SJ, Choi J-W, Shin A, Lee YJ. Use of sedative-hypnotics and the risk of Alzheimer’s dementia: A retrospective cohort study. PLoS ONE 2018; 13(9): e0204413.
22. Linden M, Bär T, Helmchen H. Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr 2004; 16: 461–480.
23. Liu C-L, Peng L-N, Chen Y-T, Lin M-H, Liu L-K, Chen L-K.Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: a hospital-based study. Arch Gerontol Geriatr 2011; 55(1): 148–151.
24. Lucchetta RC, da Mata BPM, Mastroianni PC. Associationbetween Development of Dementia and Use of Benzodiazepines: A Systematic Review and Meta-Analysis. Pharmacotherapy 2018; 38(10): 1010–1020.
25. Luchsinger JA, Tang MX, Siddiqui M et al. Alcohol intake and risk of dementia. J Am Geriatr Soc 2004; 52: 540–546.
26. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; upad288: 1475–1483.
27. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157: 708–714.
28. Mamdani M, Rapoport M, Shulman KI, Herrmann N, Rochon PA. Mental health-related drug utilization among older adults: prevalence, trends, and costs. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry 2005; 13(10): 892–900.
29. May PC, Robison PM. GYKI 52466 protects against non- NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci Lett 1993; 152(1–2): 169–172.
30. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc 2011; 59(3): 473–481.
31. Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. Am J Psychiatry 2020; 177(6): 497–505.
32. Pariente A, de Gage SB, Moore N, Bégaud B. The Benzodiazepine– Dementia Disorders Link: Current State of Knowledge. CNS Drugs 2016; 30(1): 1–7. Epub 2015/12/31. 10.1007/ s40263-015-0305-4.
33. Pieszka M, Szczurek P, Ropka-Molik K, Oczkowicz M, Pieszka M. Rola resweratrolu w regulacji metabolizmu komórkowego. The role of resveratrol in the regulation of cell metabolism – a review. Postępy Higieny i Medycyny Doświadczalnej (Advances in Hygiene and Experimental Medicine) 2016; 70: 1117–1123.
34. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007; 29: 125–132.
35. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. 2016.
36. Richard E, Reitz C, Honig LH, Schupf N, Tang M X, Manly JJ et al. Late-life depression, mild cognitive impairment, and dementia. JAMA neurology 2013); 70(3): 374–382.
37. Stella F, Radanovic M, Balthazar ML, Canineu PR, de Souza LC, Forlenza OV. Neuropsychiatric symptoms in the prodromal stages of dementia. Curr Opin Psychiatry 2014; 27(3): 230–235.
38. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29: 639–658.
39. Tseng LY, Huang ST, Peng LN, Chen LK, Hsiao FY. Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2020; 17(1): 156–164.
40. Van Strien AM, Koek HL, van Marum RJ, Emmelot-Vonk MH. Psychotropic medications, including short acting benzodiazepines, strongly increase the frequency of falls in elderly. Maturitas 2013;74(4): 357–362.
41. Wick JY, The History of Benzodiazepines. The Consultant Pharmacist 2013; 28: 538–548.
42. Willems IA, Gorgels WJ, Oude Voshaar RC, Mulder J, Lucassen PL. Tolerance to benzodiazepines among long-term users in primary care. Fam Pract 2013; 30: 404–410.
43. World Health Organization: Dementia: A Public Health Priority. Geneva, World Health Organization 2012.
44. Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J GeriatrPsychiatry 2011; 19: 151–159.
45. Zahodne LB, Ornstein K, Cosentino S, Devanand DP, Stern Y. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/ aggression. Am J Geriatr Psychiatry 2015; 23(2): 130–140.
46. Zhong G, Wang Y, Zhang Y, Zhao Y. Association between Benzodiazepine Use and Dementia: A Meta-Analysis. PLoS One 2015; 10(5): e0127836.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.